Vistagen Therapeutics IncVistagen Therapeutics Inc
Vistagen Therapeutics Inc

Vistagen Therapeutics Inc

VTGN
Health Care·Biotechnology

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

California; U.S.A
Market cap
$11.1MNo data
Revenue
$1.3M+161.1% YoY
Net income
No dataNo data
Free cash flow
$-66.4M−57.8% YoY

Market

Listed stock
VTGNPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$1.3M+161.1% YoY
Operating income
$-72.1M−28.9% YoY
Net income
No dataNo data
Free cash flow
$-66.4M−57.8% YoY

Revenue, profit & cash trend

Revenue
Operating income
Free cash flow
Reference
Revenue: 2022 $1.1M, 2023 $176K, 2024 $1.1M, 2025 $486K, 2026 $1.3M. Operating income: 2022 $-47.8M, 2023 $-59.3M, 2024 $-33M, 2025 $-56M, 2026 $-72.1M. Free cash flow: 2022 $-45.5M, 2023 $-50.2M, 2024 $-25.8M, 2025 $-42.1M, 2026 $-66.4M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Free cash flow
Operating income: 2022-03-31 $-47.8M, 2023-03-31 $-59.3M, 2024-03-31 $-33M, 2025-03-31 $-56M, 2026-03-31 $-72.1M. Free cash flow: 2022-03-31 $-45.5M, 2023-03-31 $-50.2M, 2024-03-31 $-25.8M, 2025-03-31 $-42.1M, 2026-03-31 $-66.4M

Growth heatmap

2023202420252026CAGR
Revenue
-84.1%
+504.5%
-54.3%
+161.1%
+3.4%
Gross profit
-84.1%
+176.1%
-24.0%
Operating income
-24.0%
+44.3%
-69.5%
-28.9%
No data
Free cash flow
-10.5%
+48.6%
-63.1%
-57.8%
No data

Earnings quality

Operating cash flow
$-66.4M−57.8% YoY
Net income
No dataNo data
Free cash flow
$-66.4M−57.8% YoY
Diluted EPS
No dataNo data

Cash conversion quality

No data

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data